2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)

Yokota, Shumpei; Imagawa, Tomoyuki; Miyamae, Takako; Kasai, Kazuko; Mori, Masaaki; Nishimoto, Norihiro; Kishimoto, Tadamitsu

doi:10.1186/1546-0096-6-s1-s1

Cited by 9 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 Duration of disease (mean) was 4.8 years which was almost similar to Benedetti et al's 15 multicentered study (5.1 year) and Sujata et al's 16 study (6.1 year) from India. Most of the patients were in the age group of 6-10 years (60% of case and 86% of controls) which was also similar to Yokota et al's study 6,14 but the mean age at disease onset was a little bit lower (4.5 years) than the study done in India (8 years) by Sujata et al 16 .…”

Section: Discussionsupporting

confidence: 56%

Efficacy of Tocilizumab in the Treatment of Systemic Onset Juvenile Idiopathic Arthritis

Islam

et al. 2017

Bangladesh J Child Health

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 56%

Efficacy of Tocilizumab in the Treatment of Systemic Onset Juvenile Idiopathic Arthritis

Islam

et al. 2017

Bangladesh J Child Health

View full text Add to dashboard Cite

“…A total of 128 patients with SJIA who completed the MRA011JP and MRA316JP studies as well as another 61 patients were enrolled to evaluate the tolerability of tocilizumab, which was administered at 8 mg/kg every 2 weeks for a median duration of 78 weeks [Yokota et al 2008b]. In total, 14 patients were withdrawn from the study.…”

Section: Phase III Trials Of Tocilizumab For Systemic Juvenile Idiopamentioning

confidence: 99%

Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis

Yokota

Tanaka

Kishimoto

2012

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Clinical manifestations of systemic juvenile idiopathic arthritis and proinflammatory cytokinesSystemic manifestations with a quotidian, spiking fever, fatigue, anorexia, nonfixed erythematosus skin rash, and polyarthritis are characteristic Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis Shumpei Yokota, Toshio Tanaka and Tadamitsu Kishimoto Abstract: Systemic juvenile idiopathic arthritis (SJIA), a subtype of juvenile idiopathic arthritis, is characterized by systemic features, such as spiking fever, salmon-colored macular rash, serositis, lymphadenopathy, hepatosplenomegaly, and joint inflammation. It is also often complicated with growth retardation, osteoporosis, and sometimes macrophage activation syndrome (MAS) develops, a potentially fatal disease. Pathogenesis of SJIA and MAS is not yet fully understood, but activation of the innate immune system, which causes phagocytosis by dendritic cells, monocytes, and macrophages to produce proinflammatory cytokines such as interleukin-6 (IL-6), IL-1β and IL-18, is thought to be a primary abnormality associated with SJIA. Dysregulated production of IL-6 plays a major role in the development of systemic clinical features. The blockade of IL-6 might thus represent a novel strategy for the treatment of SJIA. Several phase II and III clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab, proved its outstanding efficacy and tolerable safety profile for SJIA refractory to conventional treatment regimens. This resulted in the approval of tocilizumab for the treatment of SJIA in Japan, India, the EU and the USA.

show abstract

“…Of 40 patients with 48-week efficacy data, 72.5% were able to reduce corticosteroid doses more than 30% and 52.5% were able to reduce corticosteroid doses more than 50%. 20,21 Tocilizumab was also associated with improvement in systemic juvenile idiopathic arthritis in an open-label, single-dose trial including 18 children 2 to 17 years of age. Patients received single-dose tocilizumab 2, 4, or 8 mg/kg by IV infusion.…”

Section: Comparative Efficacy Rheumatoid Arthritismentioning

confidence: 98%

Tocilizumab

Cada¹,

Levien²,

Baker³

2010

Hosp Pharm

View full text Add to dashboard Cite

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The June 2010 monograph topics are on rifaximin in hepatic encephalopathy, ticagrelor, fingolimod, doxepin hydrochloride tablets, and carglumic acid tablets. The DUE/MUE is on rifaximin.

show abstract

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)

Abstract: To evaluate long-term safety and efficacy of tocilizumab in treatment of children with systemic JIA.

Cited by 9 publications

References 0 publications

Efficacy of Tocilizumab in the Treatment of Systemic Onset Juvenile Idiopathic Arthritis

Efficacy of Tocilizumab in the Treatment of Systemic Onset Juvenile Idiopathic Arthritis

Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis

Tocilizumab

Contact Info

Product

Resources

About